{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:36:14Z","timestamp":1792841774066,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Foundation\u2014Flanders, Belgium","award":["1SHAA24N"],"award-info":[{"award-number":["1SHAA24N"]}]},{"name":"Research Foundation\u2014Flanders, Belgium","award":["1SF2924N"],"award-info":[{"award-number":["1SF2924N"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Infliximab is an established rescue therapy for patients with steroid-refractory acute severe ulcerative colitis (ASUC), yet optimal dosing strategies minimizing colectomy risk remain unclear. We aimed to develop a model-informed risk stratification algorithm to identify patients at high risk of colectomy within 90 days of initiating infliximab to support personalized dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, retrospective population pharmacokinetics (popPK) and exposure\u2013response study using data from patients with ASUC. A parametric time-to-event model was developed to characterize the 90-day colectomy risk. Patient characteristics and pharmacokinetic projections were evaluated as predictors. These modelling results informed the development of an algorithm for risk stratification and personalized infliximab rescue dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven medical centers contributed data from 72 patients with ASUC, yielding a total of 152 infliximab serum concentrations. Eleven patients underwent colectomy within 90 days. The strongest predictor of colectomy was the clearance-normalized exposure between weeks 2 and 4 (area under the concentration\u2013time curve, AUCw2-4 to Bayesian-forecasted infliximab clearance, CL), with an area under the receiver operating characteristic curve of 0.79 (95% confidence interval [CI], 0.52-1.00). The AUCw2-4\/CL ratio was calculated by individualizing the popPK model using the patient\u2019s body weight, baseline C-reactive protein, and infliximab concentrations. Patients with a log-transformed AUCw2-4\/CL ratio\u2009&amp;lt;\u20095.79 were classified as high risk for colectomy (sensitivity 83%, specificity 85%). Overall classification accuracy was 85% (95% CI, 74-92).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We developed a model-based dose\u2013exposure\u2013response framework to predict colectomy risk in ASUC. We integrated the algorithm into an interactive tool to enable individualized infliximab rescue therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag029","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:11:31Z","timestamp":1774329091000},"source":"Crossref","is-referenced-by-count":2,"title":["Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3385-490X","authenticated-orcid":false,"given":"Emmanuel","family":"Niyigena","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]},{"name":"Faculty of Pharmacy and Biomedical Sciences, UCLouvain , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-9484","authenticated-orcid":false,"given":"Yannick","family":"Hoffert","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0982","authenticated-orcid":false,"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6665-0857","authenticated-orcid":false,"given":"Alessandro","family":"Pedicelli","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4878","authenticated-orcid":false,"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[{"name":"Gastroenterology, University Hospital of Saint Etienne , Saint Etienne,","place":["France"]},{"name":"Clinique des C\u00e8dres MICI Institut Priv\u00e9, , \u00c9chirolles,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-8014","authenticated-orcid":false,"given":"Jurij","family":"Han\u017eel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Medical Centre Ljubljana, University of Ljubljana , Ljubljana,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-0254","authenticated-orcid":false,"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-3583","authenticated-orcid":false,"given":"Laure","family":"Elens","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Biomedical Sciences, UCLouvain , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-2044","authenticated-orcid":false,"given":"Zhigang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0274","authenticated-orcid":false,"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, La Jolla , La Jolla, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9764","authenticated-orcid":false,"given":"Robert","family":"Battat","sequence":"additional","affiliation":[{"name":"Center for Clinical Excellence and Translational Research in Inflammatory Bowel Diseases, University of Montreal Hospital Centre (CHUM) , Montreal, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026032401112782800_jjag029-B1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2026032401112782800_jjag029-B2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/ajg.2012.333","article-title":"Decreasing colectomy rates for ulcerative colitis: a population-based time trend study","volume":"107","author":"Kaplan","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026032401112782800_jjag029-B3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026032401112782800_jjag029-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"2026032401112782800_jjag029-B5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing good practices for exposure-response analysis of clinical endpoints in drug development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026032401112782800_jjag029-B6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026032401112782800_jjag029-B7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"2026032401112782800_jjag029-B8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","article-title":"Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis","volume":"19","author":"Battat","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032401112782800_jjag029-B9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2026032401112782800_jjag029-B10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"2026032401112782800_jjag029-B11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032401112782800_jjag029-B12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032401112782800_jjag029-B13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2025.07.020","article-title":"Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: results from PREDICT-UC","volume":"170","author":"Li Wai Suen","year":"2026","journal-title":"Gastroenterology"},{"key":"2026032401112782800_jjag029-B14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026032401112782800_jjag029-B15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026032401112782800_jjag029-B16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","article-title":"Serum levels of C-reactive protein in Crohn\u2019s disease and ulcerative colitis","volume":"12","author":"Fagan","year":"1982","journal-title":"Eur J Clin Invest"},{"key":"2026032401112782800_jjag029-B17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2468-1253(24)00379-0","article-title":"Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis","volume":"10","author":"Hoffert","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032401112782800_jjag029-B18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best practice for therapeutic drug monitoring of infliximab: position statement from the international association of therapeutic drug monitoring and clinical toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2026032401112782800_jjag029-B19","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"2026032401112782800_jjag029-B20","doi-asserted-by":"crossref","first-page":"i194","DOI":"10.1093\/ecco-jcc\/jjae190.0095","article-title":"DOP056 TDM-based dose-intensification of infliximab is not superior to standard dosing in patients with acute severe ulcerative colitis: results from the TITRATE study","volume":"19","author":"Gecse","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag029\/67491909\/jjag029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag029\/67491909\/jjag029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:11:33Z","timestamp":1774329093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag029\/8538874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag029","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"jjag029"}}